Articles tagged with Gene Targeting
Insilico's unified AI framework combines disease-specific predictive modeling with rigorous benchmarking to improve target identification accuracy and reliability. The validated system generates actionable intelligence, prioritizing targets with strong potential for successful development.
Researchers at VCU Massey Comprehensive Cancer Center developed a targeted therapy that effectively prevents prostate tumors from spreading to the bone. The small molecule inhibitor IVMT-Rx-4 blocks the function of MDA-9/Syntenin, preventing tumor growth and improving survival in models with bone metastasis.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Insilico Medicine showcases its Pharma.AI platform's capabilities in generating biologics and analyzing data to accelerate drug discovery. The company's latest updates include improved Generative Biologics, Chemistry42/Nach01, and PandaOmics features.
Researchers identified a targeted drug that blocks a specific genetic pathway to reverse tumor-driving cellular interactions, potentially restoring DNA function and benefiting patients with synovial sarcoma. The study's findings endorse a promising strategy to improve outcomes for this rare but deadly cancer.
Insilico Medicine has released several AI-powered tools, including PandaOmics and Generative Biologics, to accelerate drug discovery. These platforms utilize machine learning and AI models to analyze large datasets and generate novel hypotheses.
The CityUHK team is developing two core therapeutic medicines using state-of-the-art DNA surgery technology to treat liver and cardiovascular genetic diseases. Their approach offers a durable and long-lasting solution, eliminating the need for repeated medications.
Insilico Medicine's founder Alex Zhavoronkov, PhD, is named among 100 global leaders driving the future of artificial intelligence. The company has developed breakthrough solutions for novel target discovery and drug development using generative AI.
Researchers developed photo-inducible binary interaction tools (PhoBITs) to precisely control gene expression, cell signaling, and immune responses. PhoBITs enable targeted treatment with minimal side effects, opening new avenues for cancer therapy, immunotherapy, and regenerative medicine.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
The study identified ZmMPK3 as a positive regulator of salt stress response in maize. The ZmMPK3-ZmGRF1 module enhances cell proliferation under saline environments, promoting maize growth.
Researchers have discovered that TAF2 plays a pivotal role in the growth of liver cancer and can help promote tumor formation. The study's findings suggest that targeting TAF2 could lead to more effective treatments for liver cancer.
Researchers argue that deliberate full extinction might be acceptable in rare cases, but only with careful consideration of ecological and moral implications. The study calls for robust ethical safeguards and inclusive decision-making frameworks to guide the use of genetic modification technologies.
A new gene therapy has successfully restored immune function in nine children with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. The treatment has eliminated symptoms and reduced severe infections, offering a life-changing benefit to these patients.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
Researchers have discovered that inhibiting the metalloprotease ADAM19 can reduce gut inflammation and cell aging markers across species. The study found that blocking ADAM19 reduced gut damage and inflammation in fruit flies, mice, and human cells, offering a promising path for creating treatments to maintain healthy tissues.
A study found that genetic predisposition to higher muscle strength is associated with lower all-cause and cardiovascular mortality in aging men. The association remained significant even after adjusting for lifestyle factors such as smoking and body mass index.
A study from Weill Cornell Medicine found that healthcare providers working together in Accountable Care Organizations (ACOs) saved Medicare between $4.1 billion and $8.1 billion from 2012 to 2019. The program incentivized clinicians and organizations to improve patient care, resulting in lower medical spending per patient over time.
A global research initiative analyzing data from nearly 2 million people in diverse populations worldwide has uncovered multiple new genes associated with osteoarthritis. The study also identified key genetic pathways and 69 genes whose protein products are targeted by approved drugs, paving the way for repurposed treatments.
Researchers at MIT developed a control circuit that can precisely regulate gene expression levels, improving the efficacy and safety of gene therapy treatments. The 'COMMAND' circuit uses microRNA to suppress gene expression, allowing for tighter control over treatment outcomes.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
Researchers found that high-grade pre-cancer lesions triggered stronger immune responses and showed higher levels of immune-related markers PD-L1 and FOXP3. These findings suggest that HPV may begin avoiding the immune system early in infection, allowing infected cells to grow and potentially leading to cancer.
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
Researchers develop nanoparticle-based therapy combining hydroxyl-enriched fullerenol and mTOR inhibitors to disrupt cancer cells' organelle communication system. The approach triggers a synergistic "nanomaterial + metabolic modulation" anticancer strategy, establishing a new hope for treating aggressive cancers.
A new study reports on five patients with Canavan disease who have a novel variant identified through targeted long-read sequencing, revealing an SVA_E retrotransposable element that disrupts gene function. The findings enhance genetic diagnostics and enable improved guidance for families.
Three UTA faculty members, Kyrah Brown, Ben Jones, and J. Ping Liu, received top honors for their groundbreaking research contributions. Brown's interdisciplinary work focuses on reproductive and cardiac health among women, while Jones' research explores neutrinos to understand the universe's mysteries.
Researchers have developed a nanophotonic platform that improves the efficiency of nonlinear-optical quantum teleportation by reducing light levels and operating with single photons. The technology transmits quantum information with 94% fidelity, outperforming theoretical limits of linear optical components.
Researchers have discovered genetic properties in prostate cancer that can be targeted to improve patient outcomes, particularly for Chinese men. The findings highlight the potential of precision medicine and more effective treatments.
Professor Sun has been recognized for her transformative advancements in devices used for disease diagnosis, communication, and military safety. Her multidisciplinary research has secured over $8 million in external funding from premier organizations.
Researchers have discovered a new druggable cancer target, NPM1, which is expressed on the surface of malignant AML cells. Monoclonal antibodies targeting NPM1 showed robust anti-tumor activity in multiple in vivo models of AML, with no apparent toxicity to non-cancerous blood cells and stem cells.
A research team at the California NanoSystems Institute has created the most detailed 3D map yet of the flagellum on Trypanosoma brucei, which causes sleeping sickness. The study identified 154 different proteins that make up the flagellum, including 40 unique to the parasite.
Researchers at UT Arlington's CIHI are developing innovative solutions to address complex health needs in children with disabilities, behavioral health issues, and medical conditions. The projects aim to improve healthcare services, enhance quality of life, and promote healthier aging through cutting-edge research and model organisms.
Mass General Brigham researchers developed a machine learning algorithm, PAMmla, to predict properties of genome editing enzymes. The approach helps reduce off-target effects and improves editing safety and efficiency, enabling customized enzymes for new therapeutic targets.
A new method for DNA detection uses heterogeneous probe particles and laser light to accelerate genetic analysis. This PCR-free technique offers greater sensitivity and speed than traditional methods, making it more accessible for medical, environmental, and personal health applications.
Bacteria use tactile sensors to detect surfaces and trigger biochemical signals for colonization. Understanding mechanosensing is crucial for improving gut health and preventing biofouling in industries.
The American Heart Association funds research teams to investigate how risk factors for cardiovascular and kidney diseases impact women differently. The project aims to understand the biological significance of certain life cycles and societal factors on disease development.
Participants who took the supplement showed improvements in grip strength, lower body mobility, and reductions in body weight. The supplement appeared to reduce stem cell turnover, regulate immune function, and influence gene activity related to stress response.
Researchers from UT Arlington discovered that many wastewater treatment plants are unable to effectively remove dangerous microplastics, which can transport other pollutants into the environment. This poses potential long-term health impacts for humans, including cardiovascular disease and cancer.
A new study found that prenatal stress alters the expression of tiny RNA molecules in newborn blood, particularly in female children, affecting key enzymes in the brain's stress-regulation system. This may explain why some children are more vulnerable to developmental or psychiatric challenges.
A recent meta-analysis found that generative AI's diagnostic accuracy is lower than that of specialist doctors, with an average accuracy of 52.1%. The study suggests that while generative AI has the potential to support non-specialist doctors in diagnostics, further research is needed to improve its capabilities.
Researchers have discovered RNA pseudouridine as a novel diagnostic target for colorectal cancer. The study found correlations between pseudouridine modifications and clinical markers, enabling potential non-invasive diagnosis. The findings provide a molecular framework for RNA epigenetics-based stratification and targeted interventions.
A new study from Weill Cornell Medicine reveals a critical protein partnership that protects chromosome ends, regulating telomerase activity and preventing cell death. The researchers discovered that the CST complex and DNA polymerase α/primase interact to maintain telomere stability, with disruption leading to telomere abnormalities.
A new machine learning model accurately predicts the fitness of AAV capsids based on their amino acid sequence, enabling more efficient and cost-effective gene therapies. The model's robustness and generalizability have been demonstrated through tests on independent datasets, offering a promising tool for capsid engineering.
A study by Baylor College of Medicine researchers identifies 123 genes associated with increased AD risk in humans, including MTCH2, which shows promise as a potential therapeutic target. The team also found that reversing the alterations in these genes has a neuroprotective effect in living organisms.
A study co-authored by an Iowa State University professor identified a single protein that triggers chemical signals called effectors in cyst nematodes, which hijack plant cells. Disrupting this protein could severely reduce nematode infections, making it a powerful method for reducing crop damage.
Researchers developed a new method to measure changes in DNA that can help predict a person's age, focusing on how random chemical tags become over time. The study found that methylation entropy predicted age as accurately as traditional methods, with an average error of just five years.
Researchers at Tokyo University of Science have made breakthroughs in delivering gene-targeting compounds to the brain, using cholesterol-modified oligonucleotides that can penetrate the cerebral cortex beyond the blood vessels. This could lead to new treatments for diseases such as Alzheimer's and Parkinson's, as well as brain cancers.
Dr. Sabine Ehrt takes the helm of microbiology and immunology at Weill Cornell Medicine, aiming to build on the department's reputation in tuberculosis research and expand into other areas. She seeks to foster cross-disciplinary collaborations and boost junior faculty mentorship.
A new study finds that a specific genetic variation in the PTGS2 gene is associated with an increased risk of benign prostate hyperplasia (BPH) in Lebanese men. Men carrying the C version of this gene were more than twice as likely to have BPH compared to those without it.
Researchers discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective treatment. Restoring this mechanism prevents progression of HFpEF and alleviates lipid overload in heart cells, providing molecular evidence for a promising therapeutic...
Scientists have discovered a new immunotherapy strategy using type I dendritic cells to activate strong immune responses and generate immune memory against cancer. The treatment helps prevent tumor relapse in mouse models by triggering an immune memory response.
Researchers discovered that aging causes inflammation, oxidative stress, and gene disruption in the retinal pigment epithelium, a vital layer of cells in the eye. This study provides a clearer understanding of why aging leads to eye disease and introduces a reliable laboratory model for testing new therapies.
Researchers found that GSK3β becomes increasingly active in melanoma cells during treatment, helping them survive and adapt despite BRAF inhibitors. Treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth, suggesting blocking this protein could restore sensitivity to treatment.
A novel selective medium was developed to isolate Escherichia albertii, a previously uncharacterized species. The CT-PS-XR-MacConkey agar selectively differentiated E. albertii from other bacteria, including those in food samples. This finding has significant implications for the identification and study of this pathogen.
Researchers used CRISPR interference to examine every gene in the human genome and discovered a new set of genes contributing to Parkinson's disease risk. The study identified the Commander complex, which regulates lysosomal function and is implicated in PD risk, offering opportunities for new treatments.
Researchers have identified new candidate genes that could be responsible for congenital deafness, a condition affecting around one in 1,000 babies born in the UK. The study suggests that understanding these gene mutations may hold the key to devising effective treatments.
Researchers discovered that Purkinje cells in the cerebellum signal to stop tongue movement as it approaches a target, allowing for precise control of tongue movements. This understanding is crucial for developing treatments for symptoms linked to cerebellar dysfunction, such as vocal muscle spasms and speech disorders.
Researchers at St. Jude Children's Research Hospital have designed a new drug framework that selectively targets the CYP3A4 enzyme, reducing off-target effects. The discovery provides a roadmap for future drug developers to better evaluate drug interactions and selectively target CYP proteins.
Researchers have found that a specific protein modification to the immune protein MDA5 can block viral replication and reduce heart inflammation. The study's findings could lead to the development of broad-spectrum antiviral treatments that target multiple viruses.
Researchers found that inhibiting WNT signaling after the hemogenic endothelium stage enhances blood progenitor formation from pluripotent stem cells. This strategy corrects intrinsic deficiencies and brings in vitro-derived HSPCs closer to their in vivo counterparts.